So, with a continued 25% growth in depositors, Mitek could just service the banks they have now and not add any more and revs. from MD would tend to follow that growth rate. If each user tends to make more deposits year over year that would be make an added impact on revs.
Growth from 4 Qs ago is a little less than the 25%. It's O.K. but I was expecting more.
filing back in Dec... Michael Fox's letter to Ari is quite interesting...
Analyst Jeff Van Sinderen of B. Riley & Co. said in a recent note to investors that the company was poised for better performance in 2015. "We expect top line and margin growth over the next few years," Van Sinderen said.
Sorry, l don't know the specifics.
June 17, 2015
Zacks upgraded shares of ARI Network Services(NASDAQ:ARIS) from a hold rating to a buy rating in a report released on Monday. Zacks currently has $3.50 price objective on the stock.
If you notice, three pages out of six are devoted to discussing precision Ag. Investors fed up with the stock price, IMO, need to see the old ITI and the new ITI. One thing is certain. Iteris is undergoing big changes.
I'm holding ORBC and liking it! Also have ARIS and DYSL among others. Getting a permanent CEO at ITI will help. Guess I should have held HILL. Good luck! Small caps are acting better lately...
Bottom line will not grow until they craft the transformation of the company. I'd watch for the goal of 1m acres under management. It's a nascent ,hot market that is worldwide. So perhaps hundreds of millions are attainable.
It will come up to scale slowly but by 2016 we should get an idea of how rapid the growth will be. Meanwhile they are buying their own shares, building a solid backlog in legacy business and a pipeline products, patents, deals and relationships.
The risk is that it stays stuck under $2.00 but the reward could be a ten bagger, imo.
Dead money? Are you in denial of the Ag deals management says they have in the pipeline? Stay tuned. Breakout coming. 2016.
Nothing to report, but management seems to be bullish on business going forward. They seem to be getting an uptick in CLYC sales and that uptick is a more or less permanent expectation.
What differentiates Dynasil’s crystal scintillator technology is that it enables smaller, more power-efficient handheld devices with enhanced detection capabilities for both gamma and neutron radiation. The Company expects to see a diverse set of addressable market opportunities for its dual-mode products, from detection of nuclear bombs and materials at ports and border checkpoints to baggage screening and radiation detection at nuclear energy facilities.
Dynasil’s recent acquisition of vacuum coating chambers from DichroTec Thin Films LLC significantly increased our coating capacity. This allows our EMF subsidiary to consider large optic, film, fuel cell and heads up display opportunities not previously available to EMF. In addition, Dynasil’s RMD subsidiary has a proprietary process for manufacturing thin film scintillators for digital radiography.
...growing sales bookings, growing recurring revs, growing EBITDA and using some cash flows that should pay off in 2016. They seem to have another acquisition in pipeline. Have organic growth for forseeable future and with another acquisition, it should be a matter of time before market valuation responds. Looking for $8 to $10 over time. I'll probably be adding shares. I like this company and management.
Sounds like they are ramping up for some anticipated production at Hilger. So I would be expecting a ramp up in sales from Hilger in the next CC.
Also CLYK is kicking in. They are expecting an additional $1M in 2015 and to produce a $.5M CLYC backlog. Good to get some ROI in CLYK. CEO indicated that the Thermo Fisher orders will be coming in steadily for a long time to come- years.
Dichro is progressing with ongoing integration, so there's been some $$ going in to that but they are expecting it to pay off. Maybe next Q we'll get some specifics like they just reported with CLYK
I think CEO said "very soon" regarding an announcement of some sort on Xcede. So I would expect that as a catalyst to come in before next CC.
The govt. sequester is a headwind right now for the Contract segment. But on the bright side, the backlog grew big time from, I think, $28M to $36M. They already did some downsizing of expenses.
And Optometrics is going real strong.
Revs grew sequentially but margins were lower. However Sully expects the margins to go right back up.
There were no questions but it seems to me they are progressing real well overall.
They have over $3m in cash and some credit availability. Xcede is a drain for now and there is no visibility in Contract segment due to sequester but they seem to have enough to keep charging forward.The "integration investment" in Dichro should be near completion I would think.
They are not firing on all cylinders due to govt spending slow down. But that can change there is some healthy progress going on, IMO, in a lot of areas.
Next couple of Qs should be good!.
Oh! They got a patent for Xcede. So this would mean that the value of Xcede is higher as a result of that, I would think.
We have some good posters here and new ones coming aboard.
Appreciate the info on the deal whereby Entine got a tax break, a charity got some cash (and some shares) and Sulik ended up buying shares from the charity at a good price for himself, so that he may soon sell them much higher!!
My recent research from 10K indicates some "hidden" assets.
"We own a two-story, 44,000 square foot manufacturing and office facility in Ithaca, New York. We own a two-story, 17,000 square foot manufacturing and office facility in Margate, Kent, in the U.K.
The New Jersey, New York, and U.K. properties are collateral against notes payable to banks."
So there must be some Assets in the form of property equity there that's really not in the financials directly.
I also noticed that Xcede competitor, J&J now touts that their product, Evarrest , is recently approved for use on the liver.
April 6, 2015 /PRNewswire/ -- the U.S. Food and Drug Administration has approved an additional indication for Ethicon's EVARREST® Fibrin Sealant Patch, as an adjunct to hemostasis for control of bleeding during adult liver surgery.
They have a uploaded a recent video. If you listen to the warnings about the product, you may notice the Xceded patch might be preferable.
IoT may help thin film business:
NanoMarkets believes that the deployments of sensors and processors for the Internet-of-Things (IoT) are creating huge new opportunities for manufacturers of power source devices. Because of IoT, power devices such as thin-film and printed batteries, energy harvesting modules, small flexible photovoltaics panels and thermoelectric sources, which have enjoyed marginal revenues up to now, may begin generating hundreds of millions of dollars in annual revenues.